A Search Service for Abbreviation / Long Form

■ Search Result - Abbreviation : cGMP

Search Conditions:
Search Keyword : cGMP
Search Method : Exact match.
Research Area:

Results:  
Abbreviation: cGMP
Appearance Frequency: 3962 time(s)
Long forms: 72

Display Settings:
[Entries Per Page]
 per page
Page Control
Page: of
Long Form No. Long Form Research Area Co-occurring Abbreviation PubMed/MEDLINE Info. (Year, Title)
cyclic guanosine monophosphate
(2842 times)
Pharmacology
(400 times)
NO (914 times)
cAMP (516 times)
SGC (185 times)
1974 Mechanisms of lysosomal enzyme release from human leukocytes. II. Effects of cAMP and cGMP, autonomic agonists, and agents which affect microtubule function.
cyclic GMP
(847 times)
Pharmacology
(171 times)
NO (242 times)
cAMP (177 times)
ANP (62 times)
1975 Cyclic nucleotide phosphodiesterases in uterine development.
current good manufacturing practice
(169 times)
Cell Biology
(32 times)
FDA (35 times)
PET (8 times)
IND (6 times)
1989 Medical devices; patient examination glove; revocation of exemptions from the premarket notification procedures and the current good manufacturing practice regulations--FDA. Final rule.
3',5'-cyclic GMP
(21 times)
Pharmacology
(4 times)
NO (6 times)
cAMP (4 times)
L-NAME (3 times)
1979 Increased polymorphonuclear leukocyte cGMP levels induced by the human lympholine, leukocyte migration inhibitory factor (LIF).
8-bromo-cyclic GMP
(4 times)
Pharmacology
(2 times)
NO (2 times)
SNAP (2 times)
Ang II (1 time)
1994 Vasodilator-derived nitric oxide inhibits fetal calf serum- and angiotensin-II-induced growth of renal arteriolar smooth muscle cells.
Code of Good Manufacturing Practice
(4 times)
Molecular Biology
(1 time)
TGA (2 times)
HSC (1 time)
ISO (1 time)
2003 Regulation of cellular therapies: the Australian perspective.
cyclic 3':5'-GMP
(3 times)
Molecular Biology
(1 time)
LIF (2 times)
cAMP (1 time)
dbcAMP (1 time)
1975 Purification and properties of the light-activated cyclic nucleotide phosphodiesterase of rod outer segments.
cyclic nucleotides guanosine 3',5'-monophosphate
(3 times)
Neurology
(1 time)
AD (1 time)
CNG (1 time)
CSF (1 time)
1976 Cyclic guanosine 3',5'-monophosphate in the dimorphic fungus Mucor racemosus.
8-bromo-cGMP
(2 times)
Biochemistry
(1 time)
cAMP (1 time)
NMDA (1 time)
PMA (1 time)
1991 Spontaneous electrical activity regulates vasoactive intestinal peptide expression in dissociated spinal cord cell cultures.
10  cause accumulation of guanosine 3':5'-monophosphate
(2 times)
Biochemistry
(1 time)
cAMP (1 time)
PGE1 (1 time)
1975 The role of calcium in regulation of cyclic nucleotide content in human umbilical artery.
11  cell-permeable guanosine-3',5'-cyclic monophosphate
(2 times)
Neurology
(1 time)
NO (2 times)
DBcGMP (1 time)
L-NNA (1 time)
2001 The cerebrovascular response to elevated potassium--role of nitric oxide in the in vitro model of isolated rat middle cerebral arteries.
12  chemotactic response to the elastin-derived peptide, intracellular guanosine 3', 5'-monophosphate
(2 times)
Biochemistry
(2 times)
--- 1997 Elastin-derived peptide induces monocyte chemotaxis by increasing intracellular cyclic GMP level and activating cyclic GMP dependent protein kinase.
13  guanosine cyclic 3'-5' monophosphate
(2 times)
Nephrology
(1 time)
D-NMMA (1 time)
i.c.v (1 time)
mRNA (1 time)
1995 Oxytocin-induced penile erection. Role of nitric oxide.
14  8-bromo-cGMP, a membrane-permeable analogue of guanosine 3',5' cyclic monophosphate
(1 time)
Pharmacology
(1 time)
NO (1 time)
SOD (1 time)
2003 Involvement of H2O2 in superoxide-dismutase-induced enhancement of endothelium-dependent relaxation in rabbit mesenteric resistance artery.
15  8-Bromo-cyclic GMP, a membrane-permeable 3',5'-cyclic monophosphate
(1 time)
Nephrology
(1 time)
ANP (1 time)
GC-A (1 time)
PDGF (1 time)
1997 Inhibition of platelet-derived growth factor receptor tyrosine kinase by atrial natriuretic peptide.
16  8-pCPT-cGMP
(1 time)
Cardiology
(1 time)
N2-Bus (1 time)
PK (1 time)
2009 Protein kinase G modulates human myocardial passive stiffness by phosphorylation of the titin springs.
17  Ca influx, and an increase of the 3':5'-cyclic guanosine monophosphate
(1 time)
Drug Therapy
(1 time)
cAMP (1 time)
MD (1 time)
TA (1 time)
1984 Speculations on hormonal controls of magnesium homeostasis: a hypothesis.
18  Ca2+/protein modulator-dependent and -independent guanosine 3':5'-monophosphate
(1 time)
Biochemistry
(1 time)
--- 1978 Ca2+/protein modulator-dependent and -independent cyclic GMP phosphodiesterase from hog heart.
19  calcium-dependent increases in guanosine 3':5'-monophosphate
(1 time)
Drug Therapy
(1 time)
--- 1980 Phenytoin inhibition of cyclic guanosine 3':5'-monophosphate (cGMP) accumulation in neuroblastoma cells by calcium channel blockade.
20  cAMP and by the 3',5'-monophosphates of guanosine
(1 time)
Biology
(1 time)
FSR (1 time)
1999 Fluid secretion by isolated Malpighian tubules of Drosophila melanogaster Meig.: effects of organic anions, quinacrine and a diuretic factor found in the secreted fluid.
21  cAMP pulse with increased 3':5'-cyclic GMP
(1 time)
Science
(1 time)
5'-AMPMe (1 time)
1977 3':5'-cyclic AMP-dependent 3':5'-cyclic GMP accumulation in Dictyostelium discoideum.
22  cAMP synthesis and increased guanosine 3':5'-cyclic monophosphate
(1 time)
Allergy and Immunology
(1 time)
mAChR (1 time)
PGE2 (1 time)
PI (1 time)
1997 IgA from HIV+ haemophilic patients triggers intracellular signals coupled to the cholinergic system of the intestine.
23  cAMP, cyclic 3':5'-GMP
(1 time)
Anatomy
(1 time)
cAMP (1 time)
dbcAMP (1 time)
hCG (1 time)
1977 Effect of cyclic 3':5'-AMP derivatives prostaglandins and related agents on human chorionic gonadotropin secretion in human malignant trophoblast in culture.
24  catalyzes the synthesis of the second messenger guanosine 3',5'-monophosphate
(1 time)
Clinical Protocols
(1 time)
NO (1 time)
sGC (1 time)
2013 Stimulators of soluble guanylyl cyclase: future clinical indications.
25  cause a shortlasting increase in the levels of guanosie 3',5'-monophosphate
(1 time)
Psychopharmacology
(1 time)
cAMP (1 time)
1977 Stress-induced alterations of cyclic nucleotide levels in brain: effects of centrally acting drugs.
26  cell therapies according to good manufacturing practice
(1 time)
Patents as Topic
(1 time)
FDA (1 time)
hPSCs (1 time)
2013 Technological progress and challenges towards cGMP manufacturing of human pluripotent stem cells based therapeutic products for allogeneic and autologous cell therapies.
27  cells exposed to the nucleotide guanosine-3',5'-monophosphate
(1 time)
Cell Biology
(1 time)
CF (1 time)
CFTR (1 time)
CNP (1 time)
1997 C-type natriuretic peptide increases chloride permeability in normal and cystic fibrosis airway cells.
28  cells, through increased guanosine 3',5'-monophosphate
(1 time)
Metabolism
(1 time)
8-BrcGMP (1 time)
CO (1 time)
CoPP (1 time)
2014 Resveratrol induces hepatic mitochondrial biogenesis through the sequential activation of nitric oxide and carbon monoxide production.
29  cellular levels of 3',5'cyclic guanosine monophosphate
(1 time)
Neurology
(1 time)
Bp (1 time)
LPF (1 time)
1999 Cerebellar ataxia following whooping cough.
30  cellular therapies under good manufacturing practice-compliant
(1 time)
Cell Biology
(1 time)
aBMMSCs (1 time)
DPSCs (1 time)
MSCs (1 time)
2017 Isolation and prolonged expansion of oral mesenchymal stem cells under clinical-grade, GMP-compliant conditions differentially affects "stemness" properties.
31  cGMP accumulation of delta
(1 time)
Cell Biology
(1 time)
--- 1982 Nonequilibrium kinetics of a cyclic GMP-binding protein in Dictyostelium discoideum.
32  cGMP and O2 consumption were O2 consumption = -1.46 x
(1 time)
Physiology
(1 time)
--- 1997 cGMP level that reduces cardiac myocyte O2 consumption is altered in renal hypertension.
33  cGMP by activating a guanylyl cyclase, and that an enhanced
(1 time)
Dentistry
(1 time)
NE (1 time)
NO (1 time)
NOS (1 time)
2000 Adrenoceptor-activated nitric oxide synthesis in salivary acinar cells.
34  cGMP PDE was assayed at varying
(1 time)
Toxicology
(1 time)
PDE (1 time)
1995 Molecular mechanism of the lead-induced inhibition of rod cGMP phosphodiesterase.
35  cGMP phosphodiesterase functions to increase cytoplasamic
(1 time)
Biochemistry
(1 time)
GTP.Talpha (1 time)
1996 Possible stimulation of retinal rod recovery to dark state by cGMP release from a cGMP phosphodiesterase noncatalytic site.
36  cGMP-gated channels at low
(1 time)
Physiology
(1 time)
--- 2006 Cyclic nucleotide-gated ion channels in rod photoreceptors are protected from retinoid inhibition.
37  cGMP5H2O, (III), sodium guanosine 3':5'-cyclic phosphate tetrahydrate, Na(+)C10H11N5O7P(-)4H2O or Na
(1 time)
Crystallography
(1 time)
--- 2016 Purine 3':5'-cyclic nucleotides with the nucleobase in a syn orientation: cAMP, cGMP and cIMP.
38  Change in brain guanosine 3',5'-monophosphate
(1 time)
Drug Therapy
(1 time)
TRH (1 time)
1979 Change in brain guanosine 3',5'-monophosphate (cGMP) content by thyrotropin-releasing hormone.
39  Cilostazol, a potent inhibitor of guanosine 3':5'-cyclic monophosphate
(1 time)
Physiology
(1 time)
ACh (1 time)
SNP (1 time)
2002 Effects of cilostazol, a selective cyclic AMP phosphodiesterase inhibitor on isolated rabbit spinal arterioles.
40  clinical Good Manufacturing Practice
(1 time)
Ophthalmology
(1 time)
hiPSCs (1 time)
2014 Induced pluripotent stem cells as custom therapeutics for retinal repair: progress and rationale.
41  clinical pharmacology of the second messenger
(1 time)
Pharmacology
(1 time)
--- 2015 From bedside to bench--meeting report of the 7th International Conference on cGMP "cGMP: generators, effectors and therapeutic implications" in Trier, Germany, from June 19th to 21st 2015.
42  community-based growth monitoring and promotion
(1 time)
Public Health
(1 time)
CHWs (1 time)
WFA (1 time)
2014 Improving nutrition in Afghanistan through a community-based growth monitoring and promotion programme: a pre-post evaluation in five districts.
43  comparable to the presumed physiological
(1 time)
Physiology
(1 time)
--- 1995 Modulation of the cGMP-gated ion channel in frog rods by calmodulin and an endogenous inhibitory factor.
44  compared in our study for their effects on 3',5'-guanosine monophosphate
(1 time)
Psychopharmacology
(1 time)
cAMP (1 time)
GABA (1 time)
1976 Effect of desmethyldiazepam and chlordesmethyldiazepam on 3',5'-cyclic guanosine monophosphate levels in rat cerebellum.
45  compared levels of guanosine 3',5'-monophosphate
(1 time)
Ophthalmology
(1 time)
ERG (1 time)
IBMX (1 time)
1984 Cyclic nucleotide distribution in identified layers of suprafused rabbit retinas.
46  complex of guanylate cyclase, hence increasing platelet
(1 time)
Hematology
(1 time)
NO (1 time)
1995 Inhibition of Platelet Aggregation by Roussin's Black Salt, Sodium Nitroprusside and Other Metal Nitrosyl Complexes.
47  concentration, isoprenaline significantly increased the (cAMP)
(1 time)
Physiology
(1 time)
--- 2000 cAMP- and cGMP-independent stretch-induced changes in the contraction of rat atrium.
48  concentrations decreased the basal activity of a guanosine 3',5'-monophosphate
(1 time)
Biochemistry
(1 time)
CDR (1 time)
1979 Effects of spermine on activity and stability of calcium-dependent guanosine 3',5'-monophosphate phosphodiesterase.
49  consistent elevation of its presumed second messenger
(1 time)
Cardiology
(1 time)
BNP (1 time)
cDNP (1 time)
DNP (1 time)
2004 Gene transfer of a novel vasoactive natriuretic peptide stimulates cGMP and lowers blood pressure in mice.
50  contrast, ANP-induced increments in plasma and urinary second messenger
(1 time)
Vascular Diseases
(1 time)
ANP (1 time)
BNP (1 time)
1996 Differing metabolism and bioactivity of atrial and brain natriuretic peptides in essential hypertension.
51  contrast, the level of platelet guanosine 3':5'-monophosphate
(1 time)
Biochemistry
(1 time)
cAMP (1 time)
1975 Interaction of a chick skin collagen fragment (alpha1-CB5) with human platelets. Biochemical studies during the aggregation and release reaction.
52  converted to attraction by pharmacological activation of the guanosine 3',5'-monophosphate
(1 time)
Science
(1 time)
Sema III (1 time)
1998 Conversion of neuronal growth cone responses from repulsion to attraction by cyclic nucleotides.
53  corresponding dynamic responses of guanosine 3':5'-cyclic monophosphate
(1 time)
Perinatology
(1 time)
NO (1 time)
SNAP (1 time)
2003 Maturation alters cyclic nucleotide and relaxation responses to nitric oxide donors in ovine cerebral arteries.
54  cortex and on the guanosine 3':5'-monophosphate
(1 time)
Biochemistry
(1 time)
--- 1976 Properties of the guanylate cyclase-guanosine 3':5'-monophosphate system of rat renal cortex. Activation of guanylate cyclase and calcium-independent modulation of tissue guanosine 3':5'-monophosphate by sodium azide.
55  CRT in a guanosine monophosphate
(1 time)
Cell Biology
(1 time)
CRT (1 time)
P-gp (1 time)
2011 Nitric oxide and P-glycoprotein modulate the phagocytosis of colon cancer cells.
56  current EC Guidelines for Good Manufacturing Practice
(1 time)
Cell Biology
(1 time)
--- 2005 Large-scale isolation of human hepatocytes for therapeutic application.
57  current GMP
(1 time)
Transplantation
(1 time)
--- 2004 Refinement of the automated method for human islet isolation and presentation of a closed system for in vitro islet culture.
58  cyclase sts via guanine 3':5' -cyclic monophosphate
(1 time)
Pharmacology
(1 time)
sts (1 time)
1994 Indirect talk of signalling systems in endotoxicosis: cross-talk alternatives.
59  cyclase, which generates guanosine 3',5'-monophosphate
(1 time)
Cell Biology
(1 time)
CO (1 time)
HO (1 time)
MAPK (1 time)
2004 Carbon monoxide: to boldly go where NO has gone before.
60  cyclase-cyclic GMP
(1 time)
Pharmacology
(1 time)
ANF (1 time)
1989 Biochemical mechanisms of atrial natriuretic factor action.
61  cyclic 3',5'-hydrogen phosphate sodium or 8-Bromo-guanosine-3',5'-cyclophosphate sodium
(1 time)
Pharmacology
(1 time)
--- 1999 Effect of coadministration of caffeine and either adenosine agonists or cyclic nucleotides on ketorolac analgesia.
62  cyclic GMP levels
(1 time)
Endocrinology
(1 time)
CB (1 time)
NO (1 time)
SO (1 time)
2011 Effects of cannabinoid agonists on sheep sphincter of oddi in vitro.
63  cyclic guanosine inorganic monophosphate
(1 time)
Biochemistry
(1 time)
--- 1987 Adenosine stimulates guanylate cyclase activity in vascular smooth muscle cells.
64  cyclic guanosine monophosphate production
(1 time)
Biochemistry
(1 time)
VSMC (1 time)
1989 Competitive peptide antagonists of ANF-induced cyclic guanosine monophosphate production.
65  cyclic guanosine monophosphate-dependent
(1 time)
Gastroenterology
(1 time)
GCC (1 time)
2014 The multiple roles of guanylate cyclase C, a heat stable enterotoxin receptor.
66  cyclic guanosine monophosphate-phosphodiesterase
(1 time)
Ophthalmology
(1 time)
--- 1998 Defective RNA splicing resulting from a mutation in the cyclic guanosine monophosphate-phosphodiesterase beta-subunit gene.
67  cytoplasmic concentration of guanosine 3',5'-monophosphate
(1 time)
Science
(1 time)
MLC (1 time)
1995 Nitroglycerin inhibits the phosphorylation of intermediate filament proteins rather than myosin light chain on porcine coronary artery sustained contraction.
68  Dibutyryl-cyclic guanosine 5'-monophosphate
(1 time)
Allergy and Immunology
(1 time)
IL (1 time)
LPS (1 time)
MAPK (1 time)
2004 Nitric oxide post-transcriptionally up-regulates LPS-induced IL-8 expression through p38 MAPK activation.
69  influencing guanosine 3'5'-monophosphate
(1 time)
Metabolism
(1 time)
--- 1978 Alterations in rat renal cortical and medullary guanosine 3'5'-monophosphate accumulation by oxygen- and calcium-dependent and -independent mechanisms: evidence for a calcium-independent action of oxygen in renal inner medulla.
70  L-arginine-NO-cyclic GMP
(1 time)
Pharmacology
(1 time)
NO (1 time)
2004 Participation of the L-arginine-nitric oxide-cyclic GMP-ATP-sensitive K+ channel cascade in the antinociceptive effect of rofecoxib.
71  NO-sGC-cyclic GMP
(1 time)
Cardiology
(1 time)
DAMPs (1 time)
l-NAME (1 time)
TLR4 (1 time)
2014 Damage-associated molecular pattern activated Toll-like receptor 4 signalling modulates blood pressure in L-NAME-induced hypertension.
72  oxide-cyclic GMP
(1 time)
Chemistry
(1 time)
Al (1 time)
1999 Prenatal exposure to aluminum reduces expression of neuronal nitric oxide synthase and of soluble guanylate cyclase and impairs glutamatergic neurotransmission in rat cerebellum.